Table 1. Subject Characteristics.

Subject Group	NMO	MS	Control
Number attending baseline	18	15	17
Age, Range (median)	20–76 (46)	22–62 (38)	21–77 (47)
Sex	15F, 3M	11F, 4M	13F, 4M
Aquaporin-4 antibody positive	18	0	0
EDSS, range (median)	2–6 (4)	0–5 (2)	-
Disease Duration, range (median)	12–186 (57.5)	24–240 (72)	-
Number Attending Follow-up at 1 year	16	13	16
Age attending follow-up, range (median)	20–76 (46)	29–62 (40)	21–77 (47)
Number of days to follow-up, range (median)	350–456 (386)	346–420 (378)	340–430 (372)
Immunomodulation	Aza 9, Mtx 2, Pred 1, Aza+Pred 3, Mtx+Pred 3	Inf 3, Glt 6, None 6	-
Number with brain lesions at baseline MRI	13	15	-
Number with cervical spinal cord lesion at baseline MRI	14	10	-
Number with severe visual impairment (VA ≤ 0.1).	9 (4 of which had bilateral severe visual impairment)	0	-

Abbreviations:

Aza: Azathioprine

Glt: Glatiramer

Inf: β-Interferon

Mtx: Methotrexate

MS: Multiple sclerosis

NMO: Neuromyelitis optica

Pred: Prednisolone

VA: Visual Acuity.